Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud
| dc.article.end-page | 13 | en |
| dc.article.start-page | 1 | en |
| dc.citation.doi | 10.1371/JOURNAL.PONE.0309778 | en |
| dc.contributor.author | G Cohen | en |
| dc.contributor.author | B Rapoport | en |
| dc.contributor.author | S Chan | en |
| dc.contributor.author | Paul Ruff | en |
| dc.contributor.author | A Arance | en |
| dc.contributor.author | E et al | en |
| dc.date.accessioned | 2025-03-03T07:40:51Z | |
| dc.faculty | FACULTY OF HEALTH SCIENCES | en |
| dc.identifier.citation | WOS | en |
| dc.identifier.issn | 1932-6203 | en |
| dc.identifier.uri | https://hdl.handle.net/10539/44043 | |
| dc.journal.title | Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud | en |
| dc.journal.volume | 19 | en |
| dc.publisher | PUBLIC LIBRARY SCIENCE | en |
| dc.title | Pembrolizumab 400 mg every 6 weeks as firstline therapy for advanced melanoma KEYNOTE555 Results from cohort B of an openlabel phase 1 stud | en |
| dc.type | Journal Article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Journal Article.pdf
- Size:
- 598.91 KB
- Format:
- Adobe Portable Document Format
- Description:
- Bitstream uploaded by REST Client